​

Celularity Inc.

NasdaqCM:CELU Stock Report

Market Cap: US$51.7m

Celularity (CELU) Stock Overview

A regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. More details

CELU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Rewards

Earnings have grown 23.6% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap ($52M)

Volatile share price over the past 3 months compared to the US market


CELU Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Celularity Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Celularity
Historical stock prices
Current Share PriceUS$2.11
52 Week HighUS$5.22
52 Week LowUS$1.00
Beta0.74
1 Month Change17.22%
3 Month Change28.66%
1 Year Change-28.47%
3 Year Change-94.88%
5 Year Change-97.94%
Change since IPO-97.85%

Recent News & Updates

Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry

Feb 21
Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry

Recent updates

Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry

Feb 21
Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

Feb 14
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

Celularity appoints Adrian Kilcoyne as chief medical officer

Oct 03

Celularity falls after announcing fund raising deal

Sep 15

Celularity falls 10% on deal for $150M common stock offering

Sep 08

Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers

Jul 27

Shareholder Returns

CELUUS BiotechsUS Market
7D6.6%3.3%-0.1%
1Y-28.5%-9.0%13.0%

Return vs Industry: CELU underperformed the US Biotechs industry which returned -9% over the past year.

Return vs Market: CELU underperformed the US Market which returned 13% over the past year.

Price Volatility

Is CELU's price volatile compared to industry and market?
CELU volatility
CELU Average Weekly Movement14.8%
Biotechs Industry Average Movement11.4%
Market Average Movement6.4%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: CELU's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CELU's weekly volatility has decreased from 23% to 15% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1998123Bob Haririwww.celularity.com

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Celularity Inc. Fundamentals Summary

How do Celularity's earnings and revenue compare to its market cap?
CELU fundamental statistics
Market capUS$51.73m
Earnings (TTM)-US$57.89m
Revenue (TTM)US$54.22m
0.9x
P/S Ratio
-0.9x
P/E Ratio

Is CELU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CELU income statement (TTM)
RevenueUS$54.22m
Cost of RevenueUS$14.99m
Gross ProfitUS$39.23m
Other ExpensesUS$97.12m
Earnings-US$57.89m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.42
Gross Margin72.36%
Net Profit Margin-106.77%
Debt/Equity Ratio478.5%

How did CELU perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/11 21:29
End of Day Share Price 2025/07/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celularity Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Thomas ShraderBTIG
Swayampakula RamakanthH.C. Wainwright & Co.